

Course Detail

MMWR Weekly – October 21, 2016

Course Number: WB2526-10212016

Origination Date: October 21, 2016

CE Expiration Date: December 5, 2016

Content Experts/Prepares

Declines in Opioid Prescribing After a Private Insurer Policy Change — Massachusetts, 2011–2015

Macarena C. García, DrPH, Center for Surveillance, Epidemiology, and Laboratory Services, CDC

Anton B. Dodek, MD, Blue Cross Blue Shield of Massachusetts

Tom Kowalski, Blue Cross Blue Shield of Massachusetts

John Fallon, MD, Blue Cross Blue Shield of Massachusetts

Scott H. Lee, PhD, Center for Surveillance, Epidemiology, and Laboratory Services, CDC

Michael F. Iademarco, MD, Center for Surveillance, Epidemiology, and Laboratory Services, CDC

John Auerbach, MBA, Office of the Associate Director for Policy, Office of the Director, CDC

Michele K. Bohm, MPH, Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, CDC

National Progress Toward Hepatitis C Elimination — Georgia, 2015–2016

Lia Gvinjilia, MD, PhD, CDC Foundation, Tbilisi, Georgia

Muazzam Nasrullah, MD, PhD, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC

David Sergeenko, MD, Ministry of Labor Health and Social Affairs of Georgia, Tbilisi, Georgia

Tengiz Tsertsvadze, MD, PhD, Infectious Diseases, AIDS, and Clinical Immunology Research Center, Tbilisi, Georgia

George Kamkamidze, MD, PhD, Neolab, Tbilisi, Georgia

Maia Butsashvili, MD, PhD, Neolab, Tbilisi, Georgia

Amiran Gamkrelidze, MD, PhD, National Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia

Paata Imnadze, MD, PhD, National Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia

Valeri Kvaratskhelia, Ministry of Labor Health and Social Affairs of Georgia, Tbilisi, Georgia

Nikoloz Chkhartishvili, MD, PhD, Infectious Diseases, AIDS, and Clinical Immunology Research Center, Tbilisi, Georgia

Lali Sharvadze, MD, PhD, Joint Georgian-French Hepatology Clinic Hepa, Tbilisi, Georgia

Jan Drobeniuc, MD, PhD, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC

Liesl Hagan, MPH, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC

John W. Ward, MD, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC

Juliette Morgan, MD, Global Disease Detection, Division of Global Health Protection, South Caucasus CDC Office, Tbilisi, Georgia

Francisco Averhoff, MD, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC

Status of New Vaccine Introduction — Worldwide, September 2016

Anagha Loharikar, MD, Global Immunization Division, Center for Global Health, CDC

Laure Dumolard, PhD, Expanded Program on Immunization, World Health Organization

Susan Chu, PhD, Global Immunization Division, Center for Global Health, CDC

Terri Hyde, MD, Global Immunization Division, Center for Global Health, CDC

Tracey Goodman, MA, Expanded Program on Immunization, World Health Organization

Carsten Mantel, MD, Expanded Program on Immunization, World Health Organization

Vital Signs: Dental Sealant Use and Untreated Tooth Decay Among U.S. School-Aged Children

Susan O. Griffin, PhD, Division of Oral Health, National Center for Chronic Disease Prevention and Health Promotion, CDC

Liang Wei, MS, Division of Oral Health, National Center for Chronic Disease Prevention and Health Promotion, CDC

Barbara F. Gooch, DMD, Division of Oral Health, National Center for Chronic Disease Prevention and Health Promotion, CDC

Katherine Weno, DDS, Division of Oral Health, National Center for Chronic Disease Prevention and Health Promotion, CDC

Lorena Espinoza, DDS, Division of Oral Health, National Center for Chronic Disease Prevention and Health Promotion, CDC

Disclosure

CDC, our planners, and our content experts wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use.

No commercial support.

Mechanism(s) to Resolve Real and Perceived Conflicts of Interest: N/A